Cardiorenal Consideration as a Risk Factor for Heart Failure

American Journal of Cardiology

Volumn 99, Issue 6 SUPPL. 2, 2007, Pages

  Obialo, Chamberlain I ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHORUS;

ANEMIA; ARTICLE; CALCIUM BALANCE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANEMIA; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 33947246732     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.12.016     Document Type: Article

References (41)

1. United States Renal Data System. USRDS 2005, Annual Data Report (2005), National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S266
3. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., and Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
4. Cheung A.K., Sarnak M.J., Yan G., Berkoben M., Heyka R., Kaufman A., Lewis J., Rocco M., Toto R., Windus D., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65 (2004) 2380-2389
5. Muntner P., He J., Hamm L., Loria C., and Whelton P.K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 (2002) 745-753
6. Culleton B.F., Larson M.G., Wilson P.W.F., Evans J.C., Parfrey P.S., and Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56 (1999) 2214-2219
7. Shulman N.B., Ford C.E., Hall W.D., Blaufox M.D., Simon D., Langford H.G., and Schneider K.A. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection And Follow-Up Program Cooperative Group. Hypertension 13 suppl (1989) I80-I93
8. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., and Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004) 659-663
9. McAlister F.A., Ezekowitz J., Tonelli M., and Armstrong P.W. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109 (2004) 1004-1009
10. McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., and Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with cooperative heart failure admitted to community hospitals: a populations-based study. J Am Soc Nephrol 13 (2002) 1928-1936
11. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson I.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
12. Stack A.G., and Bloembergen W.E. A cross-section study of the prevalence and clinical correlates of congestive failure among incident US dialysis patients. Am J Kidney Dis 38 (2001) 991-1000
13. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S., and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
14. Adams K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., Berkowitz R.L., Galvao M., and Horton D.P. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
15. McCullough P.A. Cardio renal risk: an important clinical intersection. Rev Cardiovasc Med 3 (2002) 71-76
16. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., and Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
17. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
18. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
19. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
20. Kos T., Pacher R., Wimmer A., Bojic A., Hulsmann M., Frey B., Mayer G., Yilmaz N., Skvarilova L., Spinar J., et al. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Win Klin Wochenschr 110 (1998) 89-95
21. Hakim R.M., and Lazarus J.M. Biochemical parameters in chronic renal failure. Am J Kidney Dis 11 (1988) 238-247
22. McClellan W., Aronoff S.L., Bolton W.K., Hood S., Lorber D.L., Tang K.L., Tse T.F., Wasserman B., and Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20 (2004) 1501-1510
23. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., Brosh D., Laniado S., Schwartz D., Yachnin T., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
24. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996) 53-61
25. Silberberg J.S., Rahal D.P., Patton D.R., and Sniderman A.D. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64 (1989) 222-224
26. Levin A., Thompson C.R., Ethier J., Carlisle E.J., Tobe S., Mendelssohn D., Burgess E., Jindal K., Barrett B., Singer J., and Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34 (1999) 125-134
27. Levin A., Singer J., Thompson C.R., Ross H., and Lewis M. Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. Am J Kidney Dis 27 (1996) 347-354
28. Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11 (1996) 1277-1285
29. Keane W.F., and Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
30. Stehouwer C.D., Nauta J.J., Zeldenrust G.C., Hackeng W.H., Donker A.J., and den Ottolander G.J. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet 340 (1992) 319-323
31. Hillege H.L., Janssen W.M., Bak A.A., Deircks G.F., Grobbee D.E., Crijns H.J., Van Gilst W.H., De Zeeuw D., De Jong P.E., and Prevend Study Group. Microalbuminuria is common also in non-diabetic, non-hypertensive population and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249 (2001) 519-526
32. Mann J.F., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
33. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 139 (2003) 901-906
34. Romundstad S., Holmen J., Hallan H., Kvenild K., and Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter?. The Nord-Trondelag Health Study (HUNT), Norway. Circulation 108 (2003) 2783-2789
35. Wachtell K., Olsen M.H., Dahlof B., Devereux R.B., Kjeldsen S.E., Nieminen M.S., Okin P.M., Papademetriou V., Mogensen C.E., Borch-Johnsen K., and Ibsen H. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 20 (2002) 405-412
36. Arora K.K., Lacy J.P., Schacht R.A., Martin D.G., and Gutch C.F. Calcific cardiomyopathy in advanced renal failure. Arch Intern Med 135 (1975) 603-605
37. Block G.A., and Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35 (2000) 1478-1483
38. Davies M.R., and Hruska K.A. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 (2001) 472-479
39. London G.M., Marchais S.J., Safar M.E., Genest A.F., Guerin A.P., Metivier F., Chedid K., and London A.M. Aortic and large artery compliance in end-stage renal disease. Kidney Int 37 (1990) 137-142
40. Kuzela D.C., Huffer W.E., Conger J.D., Winter S.D., and Hammond W.S. Soft tissue calcification in chronic dialysis patients. Am J Pathol 86 (1977) 403-424
41. Rao D.S., Shih M.S., and Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 (1993) 171-175